Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity

▤ Summary

Enterome presented interim Phase 1/2 data for EO2463 at the EHA Congress. The company reported that the therapy was well tolerated and produced durable CD8 T-cell responses across monotherapy and combination cohorts in indolent non-Hodgkin lymphoma. The data also showed meaningful clinical activity, including objective response rates in both watch-and-wait and combination settings. Enterome said the immune response may serve as a predictive biomarker and stated that it is actively seeking partners and investors to advance registrational development.

▦ Linked Companies